- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
May 12, 2022Robins Kaplan Practice Group, Attorney Recognized in Elite Trial Lawyers Awards
-
May 9, 2022Six Partners Recognized as “IP Stars” by Managing Intellectual Property
-
June 2, 2022Hennepin County Bar Foundation 2022 Bar Benefit
-
June 2, 2022Lawyers Concerned for Lawyers 2022 Stepping Up Breakfast
-
June 2, 2022YWCA Minneapolis Empower Possible
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
-
May 26, 2022Fed Minutes Show Inflation-Fighting Commitment, Spur Market Rally
-
May 25, 2022Mining Giant Glencore Fined $1.1B Over Global Bribery and Price Manipulation Scheme
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New Study Shows Women Using the Ortho Evra Birth-Control Patch Double Risk of Blood Clots Compared With Those Taking Birth-Control Pill
February 17, 2006
Women using the Ortho Evra birth-control patch have twice the risk of developing blood clots than those who take the pill according to a new study funded by Ortho Women’s Health & Urology, the manufacturer of the patch. Two studies were done and interim results from the second study suggested a two fold increase in the risk of clots in the legs and lungs, in women using the patch, Ortho said.
On Feb. 16, 2006, the Food and Drug Administration approved a revision to the label for the Ortho Evra contraceptive patch, warning doctors and patients that the product exposes women to higher levels of estrogen than most birth control pills. The new warning is the result of the study that compared the risks of developing serious blood clots in women using the Ortho Evra patch with the risks caused by typical birth control pills.[1] The studies found that women who use Ortho Evra are exposed to about 60 percent more total estrogen in their blood than if they were taking a typical birth control pill.[2] High levels of estrogen levels are associated with an increased risk of developing potentially fatal blood clots (strokes). The company said that the risk of clots remains rare and that they have been reported as a potential risk of all hormonal contraceptives.
This new bolder warning comes just months after the Nov. 10, 2005 FDA change to the label on the Ortho Evra patch to reflect that women using it had higher risk of blood clots and other side effects because they are exposed to more estrogen than women taking the pill. An Associated Press investigation published in July 2005 reported that women on the Ortho Evra patch were three times more likely to die or be injured by a blood clot than women on the pill.[3] The AP report indicated that potential Ortho Evra patch deaths have been reported in about a dozen young women in 2004.[4] According to the Associated Press, annual American sales of the Ortho Evra patch reached an estimated $400 million.[5]
The new Ortho Evra labeling information is available along with additional information for healthcare providers and consumers online at: www.fda.gov/cder/drug/infopage/orthoevra/default.htm. If you or someone you know has been injured or killed by a blood clot while using Ortho Evra patch and you wish to consult with us, please call our lawyers currently handling drug lawsuits: Gary Wilson at 612.349.8413 and Tara Sutton at 612.349.8577. You can also send them an e-mail by clicking on this link: contact us.
[2] “FDA Updates Labeling for Ortho Evra Contraceptive Patch,” FDA News,
[3] Martha Mendoza, “Birth Control Patch May Have Higher Risk,” The Associated Press, July 16, 2005
[4] Martha Mendoza, “Birth Control Patch May Have Higher Risk,” The Associated Press, July 16, 2005
[5] Martha Mendoza, “Birth Control Patch May Have Higher Risk,” The Associated Press, July 16, 2005
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Gary L. Wilson
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.